参考文献/References:
[1]Gagnon N,Mansour S,Bitton Y,et al.Takotsubo-like cardiomyopathy in a large cohort of patients with pheochromocytoma and paraganalioma[J].Endocrine Practice,2017,23(10):1178-1192.[2]Lenders JW,Eisenhofer G,Mannelli M,et al.Phaeochromocytoma[J].Lancet,2005,366(9486):665-675.[3]Ghadri JR,Wittstein IS,Prasad A,et al.International expert consensus document on takotsubo syndrome (part I):clinical characteristics, diagnostic criteria, and pathophysiology[J].Eur Heart J,2018,39(22):2032-2046.[4]Akashi YJ,Ishihara M.Takotsubo syndrome: insights from Japan[J].Heart Fail Clin,2016,12(4):587-595.[5]Zhang R,Gupta D,Albert SG.Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature[J].Int J Cardiol,2017(249):319-323.[6]Y-Hassan S,Falhammar H.Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas[J].J Clin Med,2020,9(8):E2435.[7]Pelliccia F,Sinagra G,Elliott P,et al.Takotsubo is not a cardiomyopathy[J].Int J Cardiol,2018(254):250-253.[8]Batisse-Lignier M,Pereira B,Motreff P,et al.Acute and chronic pheochromocytoma-induced cardiomyopathies: different prognoses? : asystematic analytical review[J].Medicine(Baltimore),2015,94(50):e2198.[9]Madias JE.Potential drugs for the management of patients with takotsubo syndrome[J].Int J Cardiol,2016(221):12-13.[10]Nef HM,Mollmann H,Kostin S,et al.Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery[J].Eur Heart J,2007,28(20):2456-2464.[11]Gianni M,Dentali F,Grandi AM,et al.Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review[J].EurHeart J,2006,27(13):1523-1529.[12]Santos JRU,Brofferio A,Viana B,et al.Catecholamine-induced cardiomyopathy in pheochromocytoma: how to manage a rare complication in a rare disease?[J].Horm Metab,2019,51(7):458-469.[13]Goico A,Chandrasekaran M,Herrera CJ.Novel developments in stress cardiomyopathy: from pathophysiology to prognosis[J].Int J Cardiol,2016(223):1053-1058.[14]Christensen TE,Bang LE,Holmvang L,et al.123I-MIBG scintigraphy in the subacute state of takotsubo cardiomyopathy[J].JACC Cardiovasc Imaging,2016,9(8):982-990.[15]Agrawal S,Shirani J,Garg L,et al.Pheochromocytoma and stress cardiomyopathy: insight into pathogenesis[J].World J Cardiol,2017,9(3):255-260.[16]Kastaun S,Gerriets T,Tschernatsch M,et al.Psychosocial and psychoneuroendocrinal aspects of Takotsubo syndrome[J].Nat Rev Cardiol,2016,13(11):688-694.[17]Chen WG,Dilsizian V.Cardiac sympathetic disturbance in takotsubo cardiomyopathy: primary etiology or a compensatory response to heart failure?[J].JACC Cardiovasc Imaging,2016,9(8):991-993.[18]Chow LTC,Chow MBCY.Coronary artery myointimal dysplasia in patients with pheochromocytoma-possible causal relationship: pathophysiology and clinical implication with reference to Takotsubo cardiomyopathy and spontaneous coronary dissection[J].Cardiovasc Pathol,2018(37):45-53.[19]Loffi M,Santangelo A,Kozel M,et al.Takotsubo cardiomyopathy: one more angiographic evidence of microvascular dysfunction[J].Biomed Res Int,2018(2018):5281485.[20]Akashi YJ,Nef HM,Lyon AR.Epidemiology and pathophysiology of takotsubo syndrome[J].Nat Rev Cardiol,2015,12(7):387-397.[21]Tanabe Y,Akashi YJ.Improving the understanding of Takotsubo syndrome: consequences of diagnosis and treatment[J].Expert Rev Cardiovasc Ther,2016,14(6):737-748.[22]Agarwal V,Kant G,Hans N,et al.Takotsubo-like cardiomyopathy in pheochromocytoma[J].Int J Cardiol,2011,153(3):241-248.[23]Agarwal G,Sadacharan D,Kapoor A,et al.ardiovascular dysfunction and catecholamine cardiomyopathy in pheochromocytoma patients and their reversal following surgical cure: results of a prospective case-control study[J].Surgery,2011,150(6):1202-1211.[24]Amin HZ,Amin LZ,Pradipta A.Takotsubo cardiomyopathy: abrief review[J].J Med Life,2020,13(1):3-7.[25]Kosuge M,Ebina T,Hibi K,et al.Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction[J].J Am Coll Cardiol,2010,55(22):2514-2516.[26]Giavarini A,Chedid A,Bobrie G,et al.Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma[J].Heart,2013,99(19):1438-1444.[27]Chlus N,Cavayero C,Kar P,et al.Takotsubo cardiomyopathy: case series and literature review[J].Cureus,2016,8(6):e649.[28]Ferreira VM,Marcelino M,Piechnik SK,et al.Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction[J].J Am Coll Cardiol,2016,67(20):2364-2374.[29]Morley-Smith AC,Lyon AR.Challenges of chronic cardiac problems in survivors of takotsubo syndrome[J].Heart Fail Clin,2016,12(4):551-557.[30]Moscatelli S,Montecucco F,Carbone F,et al.An emerging cardiovascular disease: takotsubo syndrome[J].Biomed Res Int,2019(2019):6571045.[31]Otusanya O,Goraya H,Iyer P,et al.A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma[J].Oxf Med Case Reports,2015,2015(10):343-345.[32]Y-Hassan S.Clinical features and outcome of epinephrine-induced takotsubo syndrome: analysis of 33 published cases[J].Cardiovasc Revasc Med,2016,17(7):450-455.[33]Lenders JW,Duh QY,Eisenhofer G,et al.heochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2014,99(6):1915-1942.